What are the main risks and substitution threats facing procainamide hydrochloride in medical applications?

What are the main risks and substitution threats facing procainamide hydrochloride in medical applications?
Procainamide hydrochloride faces significant substitution pressure in its primary medical use as a local anesthetic. Lidocaine offers stronger potency, longer duration, and better tissue penetration, making it the preferred choice in dental block anesthesia. Tetracaine, though more toxic, dominates surface anesthesia due to superior mucosal absorption. Procaine's limitations—poor diffusion, inability to penetrate mucous membranes, and ester-type allergy potential—have led to its gradual abandonment in developed regions. However, procaine retains niche roles in infiltration anesthesia and as a vasodilator adjunct when combined with epinephrine. The antiarrhythmic form, procainamide hydrochloride (distinct from procaine), still has clinical use but faces competition from newer Class III agents. This substitution trend caps volume growth, making procainamide more of a specialty, cost-sensitive API rather than a high-growth product.